Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study

Autoimmunity Reviews

Volumn 15, Issue 10, 2016, Pages 983-993

  Musset, Lucile ^a   Allenbach, Yves ^b,c   Benveniste, Olivier ^b,c   Boyer, Olivier ^d,e,f   Bossuyt, Xavier ^g,h   Bentow, Chelsea ⁱ   Phillips, Joe ⁱ   Mammen, Andrew ^j   Van Damme, Philip ^g,k   Westhovens, René ^g,l   Ghirardello, Anna ^m   Doria, Andrea ^m   Choi, May Y ⁿ   Fritzler, Marvin J ⁿ   Schmeling, Heinrike ⁿ   Muro, Yoshinao ^o   García De La Torre, Ignacio ^p   Ortiz Villalvazo, Miguel A ^q   Bizzaro, Nicola ^r   Infantino, Maria ^s   Imbastaro, Tiziana ^t   Peng, Qinglin ^u   Wang, Guochun ^u   Vencovský, Jiří ^v   Klein, Martin ^v   Krystufkova, Olga ^v   Franceschini, Franco ^w,x   Fredi, Micaela ^w,x   Hue, Sophie ^y   Belmondo, Thibaut ^y   Danko, Katalin ^z   Mahler, Michael ⁱ   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

^e faculté mixte de médecine et de pharmacie de Rouen   (France)

^f UNIVERSITY OF ROUEN   (France)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY OF LEUVEN   (Belgium)

ⁱ INOVA DIAGNOSTICS INC   (United States)

^j NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

^k KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^l SKELETAL BIOLOGY AND ENGINEERING RESEARCH CENTER   (Belgium)

^m UNIVERSITY OF PADOVA   (Italy)

ⁿ UNIVERSITY OF CALGARY   (Canada)

^o NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^p HOSPITAL GENERAL DE OCCIDENTE   (Mexico)

^q HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

^r San Antonio Hospital   (Italy)

^s S Giovanni di Dio Hospital   (Italy)

^t Laboratory of Autoimmune Disease Diagnostics   (Italy)

^u CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^v CHARLES UNIVERSITY   (Czech Republic)

^w UNIVERSITY OF BRESCIA   (Italy)

^x UNIVERSITY OF PAVIA   (Italy)

^y HENRI MONDOR HOSPITAL   (France)

^z UNIVERSITY OF DEBRECEN   (Hungary)

more..

Author keywords

Autoantibodies; Autoimmune myositis; HMGCR; Immune mediated necrotizing myopathy; Statins

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HMGCR PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; AGED; BELGIUM; CANADA; CHINA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CZECH REPUBLIC; DISEASE ASSOCIATION; DISEASE CONTROL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FRANCE; GEOGRAPHIC DISTRIBUTION; HUMAN; HUNGARY; IMMUNOASSAY; IMMUNOPATHOLOGY; ITALY; JAPAN; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; MUSCLE BIOPSY; MUSCLE NECROSIS; MYOPATHY; MYOSITIS; NOMENCLATURE; PHENOTYPE; PREVALENCE; PROTEIN EXPRESSION; REVIEW; SEX RATIO; ANIMAL; AUTOIMMUNE DISEASE; CHEMICALLY INDUCED; IMMUNOLOGY; METABOLISM; MULTICENTER STUDY (TOPIC); MUSCLE DISEASE; NECROSIS; RECEIVER OPERATING CHARACTERISTIC;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BIOMARKERS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MULTICENTER STUDIES AS TOPIC; MUSCULAR DISEASES; NECROSIS; ROC CURVE;

EID: 84981717423     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2016.07.023     Document Type: Review

References (72)

1. [1] Casciola-Rosen, L., Mammen, A.L., Myositis autoantibodies. Curr Opin Rheumatol 24 (2012), 602–608.
2. [2] Mammen, A.L., Dermatomyositis and polymyositis. Ann N Y Acad Sci 1184 (2010), 134–153.
3. [3] Ghirardello, A., Bassi, N., Palma, L., Borella, E., Domeneghetti, M., Punzi, L., et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep, 15, 2013 [335-0335].
4. [4] Mammen, A.L., Statin-associated autoimmune myopathy. N Engl J Med 374 (2016), 664–669.
5. [5] Lazarou, I.N., Guerne, P.A., Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 40 (2013), 550–564.
6. [6] Mahler, M., Miller, F.W., Fritzler, M.J., Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13 (2014), 367–371.
7. [7] Love, L.A., Leff, R.L., Fraser, D.D., Targoff, I.N., Dalakas, M., Plotz, P.H., et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70 (1991), 360–374.
8. [8] Monach, P.A., ANCA-associated vasculitis: a prothrombotic state even in remission?. J Rheumatol 40 (2013), 1935–1937.
9. [9] Hervier, B., Benveniste, O., Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep, 15, 2013 [349-0349].
10. [10] Thanou-Stavraki, A., James, J.A., Primary Sjogren's syndrome: current and prospective therapies. Semin Arthritis Rheum 37 (2008), 273–292.
11. [11] Cavagna, L., Nuno, L., Scire, C.A., Govoni, M., Longo, F.J., Franceschini, F., et al. Clinical spectrum time course in anti Jo-1 positive antisynthetase syndrome: results from an international retrospective multicenter study. Medicine (Baltimore), 94, 2015, e1144.
12. [12] Ghirardello, A., Rampudda, M., Ekholm, L., Bassi, N., Tarricone, E., Zampieri, S., et al. Diagnostic performance and validation of autoantibody testing in myositis by a commercial line blot assay. Rheumatology (Oxford) 49 (2010), 2370–2374.
13. [13] Betteridge, Z., Mchugh, N., Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med, 2015 [EPub ahead of print].
14. [14] Christopher-Stine, L., Casciola-Rosen, L.A., Hong, G., Chung, T., Corse, A.M., Mammen, A.L., A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy. Arthritis Rheum 62 (2010), 2757–2766.
15. [15] Mammen, A.L., Chung, T., Christopher-Stine, L., Rosen, P., Rosen, A., Doering, K.R., et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum 63 (2011), 713–721.
16. [16] Allenbach, Y., Drouot, L., Rigolet, A., Charuel, J.L., Jouen, F., Romero, N.B., et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore) 93 (2014), 150–157.
17. [17] Ulivieri, C., Baldari, C.T., Statins: from cholesterol-lowering drugs to novel immunomodulators for the treatment of Th17-mediated autoimmune diseases. Pharmacol Res 88 (2014), 41–52.
18. [18] Endo, A., A historical perspective on the discovery of statins. Proc Jpn Acad Ser B Phys Biol Sci 86 (2010), 484–493.
19. [19] Chatzizisis, Y.S., Koskinas, K.C., Misirli, G., Vaklavas, C., Hatzitolios, A., Giannoglou, G.D., Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 33 (2010), 171–187.
20. [20] Zhang, H., Plutzky, J., Turchin, A., Discontinuation of statins in routine care settings. Ann Intern Med 159 (2013), 75–76.
21. [21] Taylor, B.A., Thompson, P.D., Muscle-related side-effects of statins: from mechanisms to evidence-based solutions. Curr Opin Lipidol 26 (2015), 221–227.
22. [22] Mygland, A., Ljostad, U., Krossnes, B.K., Persisting weakness after withdrawal of a statin. BMJ Case Rep, 2014, 2014, 10.1136/bcr-2013-203094.:bcr2013203094 [pii: bcr2013203094].
23. [23] Stenzel, W., Goebel, H.H., Aronica, E., Immune-mediated necrotizing myopathies—a heterogeneous group of diseases with specific myopathological features. Neuropathol Appl Neurobiol 38 (2012), 632–646.
24. [24] Hamann, P., Cooper, R., Mchugh, N., Chinoy, H., Statin-induced necrotizing myositis—a discrete autoimmune entity within the “statin-induced myopathy spectrum”. Autoimmun Rev 12 (2013), 1177–1181.
25. [25] Endo, A., Kuroda, M., Tanzawa, K., Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 72 (1976), 323–326.
26. [26] Endo, A., Tsujita, Y., Kuroda, M., Tanzawa, K., Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem 77 (1977), 31–36.
27. [27] Endo, A., A gift from nature: the birth of the statins. Nat Med 14 (2008), 1050–1052.
28. [28] Greenwood, J., Steinman, L., Zamvil, S.S., Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6 (2006), 358–370.
29. [29] Bifulco, M., Endo, A., Statin: new life for an old drug. Pharmacol Res 88 (2014), 1–2.
30. [30] Furberg, C.D., Natural statins and stroke risk. Circulation 99 (1999), 185–188.
31. [31] Sulaiman, S., Khamis, M., Nir, S., Lelario, F., Scrano, L., Bufo, S.A., et al. Stability and removal of atorvastatin, rosuvastatin and simvastatin from wastewater. Environ Technol 36 (2015), 3232–3242.
32. [32] Mammen, A.L., Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol 7 (2011), 343–354.
33. [33] Lahaye, C., Beaufrere, A.M., Boyer, O., Drouot, L., Soubrier, M., Tournadre, A., Immune-mediated myopathy related to anti 3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies as an emerging cause of necrotizing myopathy induced by statins. Joint Bone Spine 81 (2014), 79–82.
34. [34] Werner, J.L., Christopher-Stine, L., Ghazarian, S.R., Pak, K.S., Kus, J.E., Daya, N.R., et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum 64 (2012), 4087–4093.
35. [35] Alshehri, A., Choksi, R., Bucelli, R., Pestronk, A., Myopathy with anti-HMGCR antibodies: perimysium and myofiber pathology. Neurol Neuroimmunol Neuroinflamm, 2, 2015, e124.
36. [36] Dobbels, L., Van, D.P., Mahler, M., Bossuyt, X., A 62-year-old woman with muscle weakness. Clin Chem 61 (2015), 1133–1135.
37. [37] Levenson, V.V., Biomarkers for early detection of breast cancer: what, when, and where?. Biochim Biophys Acta, 2007.
38. [38] Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., et al. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med 359 (2008), 789–799.
39. [39] Mohassel, P., Mammen, A.L., Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. Muscle Nerve 48 (2013), 477–483.
40. [40] Musset, L., Miyara, M., Benveniste, O., Charuel, J.L., Shikhman, A., Boyer, O., et al. Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies. J Immunol Res, 2014, 2014, 405956.
41. [41] Drouot, L., Allenbach, Y., Jouen, F., Charuel, J.L., Martinet, J., Meyer, A., et al. Exploring necrotizing autoimmune myopathies with a novel immunoassay for anti-3-hydroxy-3-methyl-glutaryl-CoA reductase autoantibodies. Arthritis Res Ther, 16, 2014, R39.
42. [42] Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). N Engl J Med 292 (1975), 403–407.
43. [43] Danielsson, O., Lindvall, B., Gati, I., Ernerudh, J., Classification and diagnostic investigation in inflammatory myopathies: a study of 99 patients. J Rheumatol 40 (2013), 1173–1182.
44. [44] Mahler, M., Fritzler, M.J., Bluthner, M., Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther 7 (2005), R19–R29.
45. [45] van den Hoogen, F., Khanna, D., Fransen, J., Johnson, S., Baron, M., Tyndall, A., et al. Classification criteria for systemic sclerosis: an ACR-EULAR collaborative initiative. Arthritis Rheum 65 (2013), 2737–2747.
46. [46] Mahler, M., Fritzler, M.J., Epitope specificity and significance in systemic autoimmune diseases. Ann N Y Acad Sci 1183 (2010), 267–287.
47. [47] Mahler, M., Ngo, J., Schulte-Pelkum, J., Luettich, T., Fritzler, M.J., Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther, 10, 2008, R131.
48. [48] Mahler, M., Meroni, P.L., Bossuyt, X., Fritzler, M.J., Current concepts and future directions for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. J Immunol Res, 2014, 2014, 315179.
49. [49] Albayda, J., Christopher-Stine, L., Identifying statin-associated autoimmune necrotizing myopathy. Cleve Clin J Med 81 (2014), 736–741.
50. [50] Bergua, C., Chiavelli, H., Simon, J.P., Boyer, O., Jouen, F., Stenzel, W., et al. Immune-mediated necrotizing myopathy. Z Rheumatol, 2016.
51. [51] Bentow, C., Swart, A., Wu, J., Seaman, A., Manfredi, M., Infantino, M., et al. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta 424 (2013), 141–147.
52. [52] Arbuckle, M.R., McClain, M.T., Rubertone, M.V., Scofield, R.H., Dennis, G.J., James, J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349 (2003), 1526–1533.
53. [53] McClain, M.T., Arbuckle, M.R., Heinlen, L.D., Dennis, G.J., Roebuck, J., Rubertone, M.V., et al. The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 50 (2004), 1226–1232.
54. [54] Watanabe, Y., Suzuki, S., Nishimura, H., Murata, K.Y., Kurashige, T., Ikawa, M., et al. Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies: an observational study in Japan. Medicine (Baltimore), 94, 2015, e416.
55. [55] Todd, G.R.G., McAteer, E.J., Jack, C.M., Haire, M., Roberts, S.D., Buchanan, K.D., Pulmonary hypertension, systemic lupus erythematosus, and the contraceptive pill. Ann Rheum Dis 44 (1985), 266–267.
56. [56] Grable-Esposito, P., Katzberg, H.D., Greenberg, S.A., Srinivasan, J., Katz, J., Amato, A.A., Immune-mediated necrotizing myopathy associated with statins. Muscle Nerve 41 (2010), 185–190.
57. [57] Klein, M., Mann, H., Plestilova, L., Zamecnik, J., Betteridge, Z., Mchugh, N., et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology (Oxford) 54 (2015), 2010–2014.
58. [58] Sultan, S.M., Isenberg, D.A., Re-classifying myositis. Rheumatology (Oxford) 49 (2010), 831–833.
59. [59] Basharat, P., Christopher-Stine, L., Immune-mediated necrotizing myopathy: update on diagnosis and management. Curr Rheumatol Rep, 17, 2015, 72.
60. [60] Allenbach, Y., Benveniste, O., Autoantibody profile in myositis. Rev Med Interne 35 (2014), 437–443.
61. [61] Hochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum, 40, 1997, 1725.
62. [62] Petri, M., Orbai, A.M., Alarcon, G.S., Gordon, C., Merrill, J.T., Fortin, P.R., et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64 (2012), 2677–2686.
63. [63] Walker, J.G., Pope, J., Baron, M., Leclercq, S., Hudson, M., Taillefer, S., et al. The development of systemic sclerosis classification criteria. Clin Rheumatol 26 (2007), 1401–1409.
64. [64] Amigues, J.M., Cantagrel, A., Abbal, M., Mazieres, B., Comparative study of 4 diagnosis criteria sets for mixed connective tissue disease in patients with anti-RNP antibodies. Autoimmunity Group of the Hospitals of Toulouse. J Rheumatol 23 (1996), 2055–2062.
65. [65] Aletaha, D., Neogi, T., Silman, A.J., Funovits, J., Felson, D.T., Bingham, C.O. III, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 62 (2010), 2569–2581.
66. [66] Walker, U.A., Tyndall, A., Czirjak, L., Denton, C.P., Farge, B.D., Kowal-Bielecka, O., et al. Clinical risk assessment of organ manifestations in systemic sclerosis—a report from the EULAR Scleroderma Trials and Research (EUSTAR) group data base. Ann Rheum Dis 66 (2007), 754–763.
67. [67] Mammen, A.L., Pak, K., Williams, E.K., Brisson, D., Coresh, J., Selvin, E., et al. Rarity of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects. Arthritis Care Res 64 (2012), 269–272.
68. [68] Landon-Cardinal, O., Troyanov, Y., Fritzler, M.J., Ferreira, J., Targoff, I.N., Rich, E., et al. Atorvastatin-induced autoimmune myopathy: an emerging dominant entity in patients with autoimmune myopathy presenting with a pure polymyositis phenotype. Arthritis Rheum, 67, 2015, A2539 [Suppl].
69. [69] Hengstman, G.J., ter Laak, H.J., Vree Egberts, W.T., Lundberg, I.E., Moutsopoulos, H.M., Vencovsky, J., et al. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65 (2006), 1635–1638.
70. [70] Suzuki, S., Nishikawa, A., Kuwana, M., Nishimura, H., Watanabe, Y., Nakahara, J., et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis, 10, 2015, 61.
71. [71] Wang, L., Liu, L., Hao, H., Gao, F., Liu, X., Wang, Z., et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord 24 (2014), 335–341.
72. [72] Griggs, R.C., Askanas, V., DiMauro, S., Inclusion body myositis and myopathies. Ann Neurol 38:5 (1995), 705–713.